MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 55

2011-2013

Department of Medicine

55

in Patients Who Have Failed or are

Cardiovascular
Medicine cont.

Principal Investigator

unsuitable for Vitamin K Antagonist

Genetic analysis of the differential

Treatment, AVERROSE, $31,706,

Arun Kumar, MD

efforts of NifM, a PPIase, on its

03/28/2008 to 04/30/2014

substrates, National Science

Primary Investigator
A Randomized, Double-Blind, PlaceboControlled, Parallel-Group, Multicenter
Study to Evaluate Cardiovascular
Outcomes During Treatment with
Lixisendatide in Type 2 Diabetic
Patients After an Acute Coronary
Syndrome, Sanofi-Aventis, $114,560,
08/27/2010 to 01/10/2013
Sub-Investigator
A Multicenter Randomized, DoubleBlind, Placebo-Controlled Study to
Evaluate the Safety and Efficacy
of SCH 530348 in Addition to
Standard of Care in Subjects With
Acute Coronary Syndrome: Thrombin
Receptor Antagonist for Clinical Event
Reduction in Acute Coronary Syndrome
(TRACER), Schering Plough, $186,000,
06/24/2009 to 12/05/2012
Sub-Investigator
A 104 Week, Randomized, DoubleBlind, Placebo-Controlled, ParallelGroup, Multicenter Study to Evaluate
the Efficacy of Aliskiren on the
Progression of Atherosclerosis in
Patients with Coronary Artery Disease
When Added to Optimal Background
Therapy (AQUARIUS), Novartis
Pharmaceuticals Corp, $192,717,
12/08/2008 to 12/31/2013
Lakshmi Pulakat, PhD
Co-Principal Investigator
Impact of direct renin inhibition and
AT1R blockade on cardiovascular and
renal abnormalities associated with
insulin resistance in Ren2 rats: a
combitorial strategy that targets the
cardiometabolic syndrome, Novartis
Pharmaceutical Corporation, $754,964,
02/01/2010 to 04/30/2012
Co-Principal Investigator
Ang II and overnutrition and insulin
resistance in cardiovascular tissue,
NIH/NHLBI, $743,062, 04/11/2011 to
03/31/2013

Foundation, $387,027, 01/26/2010 to

Co-Investigator

08/31/2013

Permanent Atrial Fibrillation Outcome
Study Using Dronederone on Top of

Co-Investigator

Standard Therapy, PALLAS, Sanofi-

Interactions of the RAAS and a western

Aventis, $97,140.00, 09/20/2010 to

diet on insulin metabolic actions,

10/12/2012

BLR&D Merit Review Award, $650,000,
10/01/2012 to 09/30/2016

Primary Investigator
Medtronic Attain Ability Family

Principal Investigator

Chronic Performance Post-Approval

The mTORCI - miR-29-AT2R axis in

Study Product Surveillance Registry,

cardiovascular diseases, NIH/NHLBI,

$292,610, 01/30/2012 to 12/31/2021

$355,414, 07/03/2013 to 04/30/2014
Richard Webel, MD
Hongmin Sun, PhD

Primary Investigator

Co- Investigator

Coronary Atheroma by Intravascular

SBIR Fast-Track: Improved Long-Term

Ultrasound: Effect of Rosuvastatin

Biocompatibility of Coronary Stents

versus Atrovastatin, SATURN, $217,756,

by Plasma Coating Process, National

03/31/2008 to 08/28/2012

Institutes of Health, $282,614,
09/01/2011 to 07/31/2014

Primary Investigator
A 104 week, randomized, double-blind,

Project Director

placebo-controlled, parallel-group,

Thrombosis and Hemostasis in

multicenter study to evaluate the

Host Defense from Bacterial

efficacy of aliskiren on the progression

Infection, National Institutes of

of atherosclerosis in patients with

Health, $1,603,224, 04/04/2009 to

coronary artery disease when added

03/31/2014

to optimal background therapy,
ARQUARIS, $151,000, 12/08/2008 to

Richard Weachter, MD

12/31/2013

Principal Investigator
PROVIDE-Programming Implantable

Primary Investigator

Cardioverter Defibrillators in Patients

Treatment with ADP Receptors

with a Primary Prevention Indication to

Inhibitors: Longitudinal Assessment of

Prolong Time to First Shock, $17,900,

Treatment Patterns and Events after

07/07/2009 to 04/27/2012

Acute Coronary Syndrome, TRANSLATEACS Study, $11,750, 07/19/2010 to

Principal Investigator

02/15/2014

A Phase 3, Active (Warfarin) Controlled,
Randomized, Double-Blind, Parallel

Principal Investigator

Arm study to Evaluate Efficacy and

A Randomized, double-blind, placebo-

Safety of Apixaban in Preventing Stroke

controlled, event driven trial of

and Systemic Embolism in Subjects

quarterly subcutaneous canakinuab

with Non-valvular Atrial Fibrillation,

in the prevention of recurrent

Aristotle, $332,688, 08/01/2007 to

cardiovascular events among stable

10/28/2013

post-myocardial infarction patients
with elevated hsCRP, CANTOS,

Principal Investigator

$110,253, 09/01/2010 to 06/30/2016

A Randomized Double-Blind Trial
to Evaluate Apixaban Versus ASA to

Principal Investigator

Reduce the Rate of Embolic Stroke

Primary Investigator: Placebo